Example: Heart Attack

Clinical Trials on Stomach Neoplasms

Total 2109 results





    • NCT04566393
      Available
      Expanded Access to Ulixertinib (BVD-523) in Patients With Advanced MAPK Pathway-Altered Malignancies
      Conditions: Pancreatic Cancer; Small Bowel Cancer; Colorectal Cancer; Melanoma; Non Small Cell Lung Cancer; Thyroid Cancer; Bladder Cancer; Head and Neck Cancer; Gastric Cancer; Esophageal Cancer; Cholangiocarcinoma; Ovarian Cancer; Hepatocellular Carcinoma; Glioblastoma; MAPK Gene Mutation; KRAS Activating Mutation; BRAF Gene Mutation; NRAS Gene Mutation; HRAS Gene Mutation; MEK Mutation; ERK Mutation
    • NCT04566848
      Recruiting
      The Status of Immune Checkpoints at Gastrointestinal Cancer
      Conditions: Gastrointestinal Cancer
    • NCT04567069
      Recruiting
      Safety and Efficacy Study for MG-7-DC Vaccine in Gastric Cancer Treatment
      Conditions: Gastric Cancer
    • NCT04563975
      Recruiting
      Efficacy and Safty of Toripalimab Combined With Docetaxel in Patients With Advanced Gastric Cancer
      Conditions: Gastric Cancer Stage IV
    • NCT04563416
      Recruiting
      Application of Artificial Intelligence for Early Diagnosis of Gastric Cancer During Optical Enhancement Magnifying Endoscopy
      Conditions: Artificial Intelligence; Optical Enhancement Endoscopy; Magnifying Endoscopy
    • NCT04560036
      Not yet recruiting
      FAZA PETMRI Gastro-Oesophageal Study
      Conditions: Metastasized Gastro-Oesophageal Cancer
    • NCT04561362
      Recruiting
      Study BT8009-100 in Subjects With Nectin-4 Expressing Advanced Solid Tumors Malignancies
      Conditions: Advanced Solid Tumor; Urinary Bladder Neoplasm; Pancreatic Neoplasms; Triple Negative Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Stomach Neoplasm; Esophageal Neoplasms; Ovarian Neoplasm
    • NCT04557969
      Not yet recruiting
      Prospective Study of Surgery in Gastrointestinal Stromal Tumors (GISTs) for Treatment, Tumor Modeling, and Genomic Analysis
      Conditions: Gastric Cancer; Gastric Neoplasm; Gastrointestinal Stromal Sarcoma; Gastrointestinal Stromal Neoplasm; Gastrointestinal Stromal Tumor (GIST)
    • NCT04556253
      Not yet recruiting
      AK104 in Locally Advanced MSI-H/dMMR Gastric Carcinoma and Colorectal Cancer
      Conditions: MSI-H/dMMR Gastric Carcinoma and Colorectal Cancer
    • NCT04555304
      Not yet recruiting
      Phase 2 Study of KH903 in Patients With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma As Second-Line Therapy
      Conditions: Gastric Cancer; Gastroesophageal Cancer
    • NCT04553692
      Recruiting
      Study of IGM-8444 as a Single Agent and in Combination With Chemotherapy-based Regimens in Subjects With Solid Cancers
      Conditions: Solid Tumor; Colorectal Cancer; Gastric Cancer; Non-Hodgkin's Lymphoma; Non-Small Cell Lung Cancer; Sarcoma
    • NCT04550494
      Not yet recruiting
      Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations
      Conditions: Advanced Breast Carcinoma; Advanced Malignant Solid Neoplasm; Advanced Ovarian Carcinoma; Advanced Pancreatic Carcinoma; Advanced Prostate Carcinoma; Anatomic Stage III Breast Cancer AJCC v8; Anatomic Stage IIIA Breast Cancer AJCC v8; Anatomic Stage IIIB Breast Cancer AJCC v8; Anatomic Stage IIIC Breast Cancer AJCC v8; Anatomic Stage IV Breast Cancer AJCC v8; Castration-Resistant Prostate Carcinoma; Clinical Stage III Gastric Cancer AJCC v8; Clinical Stage IV Gastric Cancer AJCC v8; Clinical Stage IVA Gastric Cancer AJCC v8; Clinical Stage IVB Gastric Cancer AJCC v8; HER2 Positive Breast Carcinoma; Metastatic Prostate Carcinoma; Pathologic Stage III Gastric Cancer AJCC v8; Pathologic Stage IIIA Gastric Cancer AJCC v8; Pathologic Stage IIIB Gastric Cancer AJCC v8; Pathologic Stage IIIC Gastric Cancer AJCC v8; Pathologic Stage IV Gastric Cancer AJCC v8; Platinum-Sensitive Ovarian Carcinoma; Postneoadjuvant Therapy Stage III Gastric Cancer AJCC v8; Postneoadjuvant Therapy Stage IV Gastric Cancer AJCC v8; Prognostic Stage III Breast Cancer AJCC v8; Prognostic Stage IIIA Breast Cancer AJCC v8; Prognostic Stage IIIB Breast Cancer AJCC v8; Prognostic Stage IIIC Breast Cancer AJCC v8; Prognostic Stage IV Breast Cancer AJCC v8; Stage II Pancreatic Cancer AJCC v8; Stage IIA Pancreatic Cancer AJCC v8; Stage IIB Pancreatic Cancer AJCC v8; Stage III Pancreatic Cancer AJCC v8; Stage III Prostate Cancer AJCC v8; Stage IIIA Ovarian Cancer AJCC v8; Stage IIIA Prostate Cancer AJCC v8; Stage IIIA1 Ovarian Cancer AJCC v8; Stage IIIA2 Ovarian Cancer AJCC v8; Stage IIIB Ovarian Cancer AJCC v8; Stage IIIB Prostate Cancer AJCC v8; Stage IIIC Ovarian Cancer AJCC v8; Stage IIIC Prostate Cancer AJCC v8; Stage IV Ovarian Cancer AJCC v8; Stage IV Pancreatic Cancer AJCC v8; Stage IV Prostate Cancer AJCC v8; Stage IVA Ovarian Cancer AJCC v8; Stage IVA Prostate Cancer AJCC v8; Stage IVB Ovarian Cancer AJCC v8; Stage IVB Prostate Cancer AJCC v8
    • NCT04547153
      Not yet recruiting
      LD-FUD for Highly Aggressive Gastric Cancer
      Conditions: Gastric Cancer; Bone Marrow Metastasis; Thrombocytopenia
    • NCT04547725
      Recruiting
      Complete Cytoreduction Followed by IP and Systemic Chemotherapies for Gastric Cancer With Peritoneal Carcinomatosis
      Conditions: Gastric Cancer; Peritoneal Carcinomatosis
    • NCT04545632
      Recruiting
      Docetaxel Ethanol-induced Symptoms; The Incidence and Risk Forecating Factor
      Conditions: Breast Cancer; NSCLC; Prostate Cancer; Head and Neck Cancer; Gastric Cancer; Esophageal Cancer; Ovarian Cancer
    • NCT04539769
      Completed
      Impact of the Type of Reconstruction Methods on Diabetes Following Laparoscopic Distal Gastrectomy in Patients With Gastric Cancer and Type 2 Diabetes
      Conditions: Stomach Neoplasms; Diabetes Mellitus, Type 2
    • NCT04535401
      Not yet recruiting
      Testing the Addition of an Anticancer Drug, BAY 1895344, to the Usual Chemotherapy in Advanced or Metastatic Cancers of the Stomach and Intestines
      Conditions: Advanced Colorectal Carcinoma; Advanced Digestive System Carcinoma; Advanced Gastric Carcinoma; Advanced Gastroesophageal Junction Adenocarcinoma; Clinical Stage III Gastric Cancer AJCC v8; Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8; Clinical Stage IV Gastric Cancer AJCC v8; Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8; Clinical Stage IVA Gastric Cancer AJCC v8; Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8; Clinical Stage IVB Gastric Cancer AJCC v8; Clinical Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8; Metastatic Colorectal Carcinoma; Metastatic Digestive System Carcinoma; Metastatic Gastric Carcinoma; Metastatic Gastroesophageal Junction Adenocarcinoma; Pathologic Stage III Gastric Cancer AJCC v8; Pathologic Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8; Pathologic Stage IIIA Gastric Cancer AJCC v8; Pathologic Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8; Pathologic Stage IIIB Gastric Cancer AJCC v8; Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8; Pathologic Stage IIIC Gastric Cancer AJCC v8; Pathologic Stage IV Gastric Cancer AJCC v8; Pathologic Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8; Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8; Pathologic Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8; Postneoadjuvant Therapy Stage III Gastric Cancer AJCC v8; Postneoadjuvant Therapy Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8; Postneoadjuvant Therapy Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8; Postneoadjuvant Therapy Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8; Postneoadjuvant Therapy Stage IV Gastric Cancer AJCC v8; Postneoadjuvant Therapy Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8; Postneoadjuvant Therapy Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8; Postneoadjuvant Therapy Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8; Stage III Colorectal Cancer AJCC v8; Stage IIIA Colorectal Cancer AJCC v8; Stage IIIB Colorectal Cancer AJCC v8; Stage IIIC Colorectal Cancer AJCC v8; Stage IV Colorectal Cancer AJCC v8; Stage IVA Colorectal Cancer AJCC v8; Stage IVB Colorectal Cancer AJCC v8; Stage IVC Colorectal Cancer AJCC v8
    • NCT04535414
      Not yet recruiting
      Phase II Randomized Trial of Bethesda Protocol Compared to Cambridge Method for Detection of Early Stage Gastric Cancer in CDH1 Mutation Carriers
      Conditions: Gastric Cancer; Gastric Neoplasms; Gastric Adenocarcinoma
    • NCT04529135
      Not yet recruiting
      The Effect of Dexmedetomidine During Opioid Free Anesthesia on Postoperative Recovery After Gastrectomy
      Conditions: Gastric Cancer
    • NCT04526886
      Not yet recruiting
      Clinical Trial of a Novel Dose Adjustment Algorithm for Preventing Cytopenia-Related Delays During FOLFOX Chemotherapy
      Conditions: Colorectal Cancer; Gastric Cancer; Esophageal Cancer; Ampullary Cancer; Small Bowel Cancer; Appendix Cancer
    • NCT04526106
      Not yet recruiting
      First-in-human Study of Highly Selective FGFR2 Inhibitor, RLY-4008, in Patients With ICC and Other Advanced Solid Tumors
      Conditions: Solid Tumor, Adult; FGFR2 Amplification; FGFR2 Gene Mutation; FGFR2 Gene Rearrangement; FGFR2 Gene Translocation; FGFR2 Gene Activation; Intrahepatic Cholangiocarcinoma; Cholangiocarcinoma; Endometrial Cancer; Gastric Cancer; Breast Cancer
    • NCT04526470
      Not yet recruiting
      Alpelisib and Paclitaxel in PIK3CA-altered Gastric Cancer
      Conditions: Solid Tumor; Stomach Cancer
    • NCT04526483
      Not yet recruiting
      L-Gastrectomy With the Intelligent Navigation 4K UHD 3D Endoscopic Imaging System
      Conditions: Stomach Neoplasms
    • NCT04523818
      Recruiting
      Short-Course Chemoradiotherapy Followed by Chemotherapy for the Treatment of Resectable Gastric Adenocarcinoma
      Conditions: Clinical Stage I Gastric Cancer AJCC v8; Clinical Stage IIA Gastric Cancer AJCC v8; Clinical Stage III Gastric Cancer AJCC v8; Clinical Stage IVA Gastric Cancer AJCC v8; Gastric Adenocarcinoma; Pathologic Stage IB Gastric Cancer AJCC v8; Pathologic Stage II Gastric Cancer AJCC v8; Pathologic Stage IIA Gastric Cancer AJCC v8; Pathologic Stage IIB Gastric Cancer AJCC v8; Pathologic Stage III Gastric Cancer AJCC v8; Pathologic Stage IIIA Gastric Cancer AJCC v8; Pathologic Stage IIIB Gastric Cancer AJCC v8; Pathologic Stage IIIC Gastric Cancer AJCC v8; Postneoadjuvant Therapy Stage I Gastric Cancer AJCC v8; Postneoadjuvant Therapy Stage II Gastric Cancer AJCC v8; Postneoadjuvant Therapy Stage III Gastric Cancer AJCC v8
    • NCT04524442
      Not yet recruiting
      Post-Authorization Safety Study (PASS) of LysaKare® in Adult Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) Patients
      Conditions: Gastroenteropancreatic Neuroendocrine Tumors
    • NCT04522011
      Not yet recruiting
      Comparison of the Efficiency Between Intraoperative and Postoperative Hyperthermic Intraperitoneal Chemotherapy With Docetaxel Combine Oxaliplatin in Patients With Advanced Gastric Cancer
      Conditions: Stomach Neoplasms; Hyperthermic Intraperitoneal Chemotherapy
    • NCT04522752
      Not yet recruiting
      Long-term Endoscopic Follow-up of Benign Epithelial Gastric Polyps
      Conditions: Benign Gastric Polyp
    • NCT04520295
      Recruiting
      ctDNA Screening in Advanced HER2 Positive Gastric Cancer
      Conditions: HER2-positive Gastric Cancer
    • NCT04519151
      Not yet recruiting
      A Phase II, Open Lable, Single Arm, Trial to Determine Efficacy and Safety of Lenvatinib in Combination With Pembrolizumab for Platinum- Sensitive Recurrent Ovarian Cancer
      Conditions: Ovarian Neoplasms; Carcinoma, Ovarian Epithelial; Neoplasm of Stomach; Ovarian Diseases; Genital Neoplasms, Female; Ovarian Epithelial Tumor; Urogenital Neoplasms; Neoplasms, Glandular and Epithelial
    • NCT04517448
      Not yet recruiting
      Quality of Life of Patients Over 75 Yars Undergoing Palliative Chemotherapy
      Conditions: Colorectal Cancer; Pancreatic Cancer; Biliary Cancer; Hepatic Cancer; Oesophageal Cancer; Gastric Cancer
    • NCT04517708
      Completed
      Effectiveness of Nutritional Interventions for Cancer Patients Undergoing Chemotherapy
      Conditions: Gastric Cancer; Colon Cancer
    • NCT04515615
      Recruiting
      Adjuvant Chemotherapy in Combination With Camrelizumab for Stage III Gastric Cancer (FOCUS-02)
      Conditions: Gastric Cancer Stage III
    • NCT04513223
      Not yet recruiting
      A Phase 1 Study of SHR-A1811 in Patients With Selected HER2 Expressing Tumors
      Conditions: Gastric Cancer; Colorectal Cancer
    • NCT04511559
      Not yet recruiting
      Methylation Analysis of Circulating Tumor DNA in Gastric Cancer
      Conditions: Stomach Neoplasms; Circulating Tumor DNA
    • NCT04511871
      Recruiting
      A Phase I Trial of CCT303-406 in Patients With Relapsed or Refractory HER2 Positive Solid Tumors
      Conditions: Solid Tumor; Gastric Cancer; Breast Cancer; Ovarian Cancer; Sarcoma
    • NCT04510064
      Recruiting
      PD-1 Antibody Combined With Modified FLOT Regimen in the Treatment of Unresectable Locally Advanced or Limited Metastatic Gastric Cancer
      Conditions: Metastatic Gastric Cancer; Locally Advanced Gastric Adenocarcinoma
    • NCT04510285
      Recruiting
      Study of Pembrolizumab Plus Trastuzumab or Trastuzumab Alone After Surgery in Patients With Esophagogastric Tumors
      Conditions: Esophagogastric Tumors; Gastric Cancer; Gastric Tumor; Esophageal Cancer; Esophageal Neoplasms; Esophageal Tumor; GastroEsophageal Cancer; Gastroesophageal Junction Adenocarcinoma; Gastroesophageal Junction Tumor; Gastroesophageal Junction Cancer
    • NCT04508140
      Recruiting
      Study of BO-112 With Pembrolizumab for Colorectal or Gastric/GEJ Cancer With Liver Metastasis
      Conditions: Colorectal Cancer; Gastric Cancer; Oesophageal Cancer
    • NCT04508686
      Recruiting
      Combination of Metronomic Capecitabine With Camrelizumab for Treatment of Refractory Solid Tumor Trial (Cohort 1)
      Conditions: HER2-negative Gastric Cancer
    • NCT04505553
      Not yet recruiting
      Oral Cryotherapy Plus Acupressure and Acupuncture Versus Oral Cryotherapy for Decreasing Chemotherapy-Induced Peripheral Neuropathy From Oxaliplatin-Based Chemotherapy in Patients With Gastrointestinal Cancer
      Conditions: Appendix Carcinoma; Colon Carcinoma; Esophageal Carcinoma; Gastric Carcinoma; Liver and Intrahepatic Bile Duct Carcinoma; Malignant Digestive System Neoplasm; Pancreatic Carcinoma; Rectal Carcinoma; Small Intestinal Carcinoma
    • NCT04503967
      Not yet recruiting
      Efficacy and Safety of Anlotinib Hydrochloride Combined With Nivolumab in the Treatment of Gastric and Esophageal Cancer
      Conditions: Gastric Adenocarcinoma; Esophageal Squamous Cell Carcinoma
    • NCT04504669
      Recruiting
      First Time in Human Study of AZD8701 With or Without Durvalumab in Participants With Advanced Solid Tumours
      Conditions: Clear Cell Renal Cell Cancer; Non-Small-Cell Lung Cancer; Triple Negative Breast Neoplasms; Squamous Cell Cancer of Head and Neck; Small Cell Lung Cancer; Gastric Cancer; Melanoma; Cervical Cancer; Advanced Solid Tumours
    • NCT04501887
      Not yet recruiting
      The Efficacy of Precision Treatment for Gastric Cancer Guided by Molecular Profiling
      Conditions: Gastric Cancer
    • NCT04501913
      Recruiting
      Remote Telemonitoring of Patient-Generated Physiologic Health Data and Patient-Reported Outcomes
      Conditions: Clinical Stage 0 Esophageal Adenocarcinoma AJCC v8; Clinical Stage 0 Esophageal Squamous Cell Carcinoma AJCC v8; Clinical Stage 0 Gastric Cancer AJCC v8; Clinical Stage I Esophageal Adenocarcinoma AJCC v8; Clinical Stage I Esophageal Squamous Cell Carcinoma AJCC v8; Clinical Stage I Gastric Cancer AJCC v8; Clinical Stage II Esophageal Adenocarcinoma AJCC v8; Clinical Stage II Esophageal Squamous Cell Carcinoma AJCC v8; Clinical Stage II Gastric Cancer AJCC v8; Clinical Stage IIA Esophageal Adenocarcinoma AJCC v8; Clinical Stage IIA Gastric Cancer AJCC v8; Clinical Stage IIB Esophageal Adenocarcinoma AJCC v8; Clinical Stage IIB Gastric Cancer AJCC v8; Clinical Stage III Esophageal Adenocarcinoma AJCC v8; Clinical Stage III Esophageal Squamous Cell Carcinoma AJCC v8; Clinical Stage III Gastric Cancer AJCC v8; Clinical Stage IV Esophageal Adenocarcinoma AJCC v8; Clinical Stage IV Esophageal Squamous Cell Carcinoma AJCC v8; Clinical Stage IV Gastric Cancer AJCC v8; Clinical Stage IVA Esophageal Adenocarcinoma AJCC v8; Clinical Stage IVA Esophageal Squamous Cell Carcinoma AJCC v8; Clinical Stage IVA Gastric Cancer AJCC v8; Clinical Stage IVB Esophageal Adenocarcinoma AJCC v8; Clinical Stage IVB Esophageal Squamous Cell Carcinoma AJCC v8; Clinical Stage IVB Gastric Cancer AJCC v8; Hepatobiliary Neoplasm; Malignant Digestive System Neoplasm; Malignant Female Reproductive System Neoplasm; Malignant Genitourinary System Neoplasm; Malignant Neoplasm; Pathologic Stage 0 Esophageal Adenocarcinoma AJCC v8; Pathologic Stage 0 Esophageal Squamous Cell Carcinoma AJCC v8; Pathologic Stage 0 Gastric Cancer AJCC v8; Pathologic Stage I Esophageal Adenocarcinoma AJCC v8; Pathologic Stage I Esophageal Squamous Cell Carcinoma AJCC v8; Pathologic Stage I Gastric Cancer AJCC v8; Pathologic Stage IA Esophageal Adenocarcinoma AJCC v8; Pathologic Stage IA Esophageal Squamous Cell Carcinoma AJCC v8; Pathologic Stage IA Gastric Cancer AJCC v8; Pathologic Stage IB Esophageal Adenocarcinoma AJCC v8; Pathologic Stage IB Esophageal Squamous Cell Carcinoma AJCC v8; Pathologic Stage IB Gastric Cancer AJCC v8; Pathologic Stage IC Esophageal Adenocarcinoma AJCC v8; Pathologic Stage II Esophageal Adenocarcinoma AJCC v8; Pathologic Stage II Esophageal Squamous Cell Carcinoma AJCC v8; Pathologic Stage II Gastric Cancer AJCC v8; Pathologic Stage IIA Esophageal Adenocarcinoma AJCC v8; Pathologic Stage IIA Esophageal Squamous Cell Carcinoma AJCC v8; Pathologic Stage IIA Gastric Cancer AJCC v8; Pathologic Stage IIB Esophageal Adenocarcinoma AJCC v8; Pathologic Stage IIB Esophageal Squamous Cell Carcinoma AJCC v8; Pathologic Stage IIB Gastric Cancer AJCC v8; Pathologic Stage III Esophageal Adenocarcinoma AJCC v8; Pathologic Stage III Esophageal Squamous Cell Carcinoma AJCC v8; Pathologic Stage III Gastric Cancer AJCC v8; Pathologic Stage IIIA Esophageal Adenocarcinoma AJCC v8; Pathologic Stage IIIA Esophageal Squamous Cell Carcinoma AJCC v8; Pathologic Stage IIIA Gastric Cancer AJCC v8; Pathologic Stage IIIB Esophageal Adenocarcinoma AJCC v8; Pathologic Stage IIIB Esophageal Squamous Cell Carcinoma AJCC v8; Pathologic Stage IIIB Gastric Cancer AJCC v8; Pathologic Stage IIIC Gastric Cancer AJCC v8; Pathologic Stage IV Esophageal Adenocarcinoma AJCC v8; Pathologic Stage IV Esophageal Squamous Cell Carcinoma AJCC v8; Pathologic Stage IV Gastric Cancer AJCC v8; Pathologic Stage IVA Esophageal Adenocarcinoma AJCC v8; Pathologic Stage IVA Esophageal Squamous Cell Carcinoma AJCC v8; Pathologic Stage IVB Esophageal Adenocarcinoma AJCC v8; Pathologic Stage IVB Esophageal Squamous Cell Carcinoma AJCC v8; Postneoadjuvant Therapy Stage I Esophageal Adenocarcinoma AJCC v8; Postneoadjuvant Therapy Stage I Esophageal Squamous Cell Carcinoma AJCC v8; Postneoadjuvant Therapy Stage II Esophageal Adenocarcinoma AJCC v8; Postneoadjuvant Therapy Stage II Esophageal Squamous Cell Carcinoma AJCC v8; Postneoadjuvant Therapy Stage III Esophageal Adenocarcinoma AJCC v8; Postneoadjuvant Therapy Stage III Esophageal Squamous Cell Carcinoma AJCC v8; Postneoadjuvant Therapy Stage IIIA Esophageal Adenocarcinoma AJCC v8; Postneoadjuvant Therapy Stage IIIA Esophageal Squamous Cell Carcinoma AJCC v8; Postneoadjuvant Therapy Stage IIIB Esophageal Adenocarcinoma AJCC v8; Postneoadjuvant Therapy Stage IIIB Esophageal Squamous Cell Carcinoma AJCC v8; Postneoadjuvant Therapy Stage IV Esophageal Adenocarcinoma AJCC v8; Postneoadjuvant Therapy Stage IV Esophageal Squamous Cell Carcinoma AJCC v8; Postneoadjuvant Therapy Stage IVA Esophageal Adenocarcinoma AJCC v8; Postneoadjuvant Therapy Stage IVA Esophageal Squamous Cell Carcinoma AJCC v8; Postneoadjuvant Therapy Stage IVB Esophageal Adenocarcinoma AJCC v8; Postneoadjuvant Therapy Stage IVB Esophageal Squamous Cell Carcinoma AJCC v8; Stage 0 Colorectal Cancer AJCC v8; Stage 0a Bladder Cancer AJCC v8; Stage 0is Bladder Cancer AJCC v8; Stage I Bladder Cancer AJCC v8; Stage I Cervical Cancer AJCC v8; Stage I Colorectal Cancer AJCC v8; Stage I Ovarian Cancer AJCC v8; Stage I Prostate Cancer AJCC v8; Stage I Renal Cell Cancer AJCC v8; Stage I Uterine Corpus Cancer AJCC v8; Stage IA Cervical Cancer AJCC v8; Stage IA Ovarian Cancer AJCC v8; Stage IA Uterine Corpus Cancer AJCC v8; Stage IA1 Cervical Cancer AJCC v8; Stage IA2 Cervical Cancer AJCC v8; Stage IB Cervical Cancer AJCC v8; Stage IB Ovarian Cancer AJCC v8; Stage IB Uterine Corpus Cancer AJCC v8; Stage IB1 Cervical Cancer AJCC v8; Stage IB2 Cervical Cancer AJCC v8; Stage IC Ovarian Cancer AJCC v8; Stage II Bladder Cancer AJCC v8; Stage II Cervical Cancer AJCC v8; Stage II Colorectal Cancer AJCC v8; Stage II Ovarian Cancer AJCC v8; Stage II Prostate Cancer AJCC v8; Stage II Renal Cell Cancer AJCC v8; Stage II Uterine Corpus Cancer AJCC v8; Stage IIA Cervical Cancer AJCC v8; Stage IIA Colorectal Cancer AJCC v8; Stage IIA Ovarian Cancer AJCC v8; Stage IIA Prostate Cancer AJCC v8; Stage IIA1 Cervical Cancer AJCC v8; Stage IIA2 Cervical Cancer AJCC v8; Stage IIB Cervical Cancer AJCC v8; Stage IIB Colorectal Cancer AJCC v8; Stage IIB Ovarian Cancer AJCC v8; Stage IIB Prostate Cancer AJCC v8; Stage IIC Colorectal Cancer AJCC v8; Stage IIC Prostate Cancer AJCC v8; Stage III Bladder Cancer AJCC v8; Stage III Cervical Cancer AJCC v8; Stage III Colorectal Cancer AJCC v8; Stage III Ovarian Cancer AJCC v8; Stage III Prostate Cancer AJCC v8; Stage III Renal Cell Cancer AJCC v8; Stage III Uterine Corpus Cancer AJCC v8; Stage IIIA Bladder Cancer AJCC v8; Stage IIIA Cervical Cancer AJCC v8; Stage IIIA Colorectal Cancer AJCC v8; Stage IIIA Ovarian Cancer AJCC v8; Stage IIIA Prostate Cancer AJCC v8; Stage IIIA Uterine Corpus Cancer AJCC v8; Stage IIIA1 Ovarian Cancer AJCC v8; Stage IIIA2 Ovarian Cancer AJCC v8; Stage IIIB Bladder Cancer AJCC v8; Stage IIIB Cervical Cancer AJCC v8; Stage IIIB Colorectal Cancer AJCC v8; Stage IIIB Ovarian Cancer AJCC v8; Stage IIIB Prostate Cancer AJCC v8; Stage IIIB Uterine Corpus Cancer AJCC v8; Stage IIIC Colorectal Cancer AJCC v8; Stage IIIC Ovarian Cancer AJCC v8; Stage IIIC Prostate Cancer AJCC v8; Stage IIIC Uterine Corpus Cancer AJCC v8; Stage IIIC1 Uterine Corpus Cancer AJCC v8; Stage IIIC2 Uterine Corpus Cancer AJCC v8; Stage IV Bladder Cancer AJCC v8; Stage IV Cervical Cancer AJCC v8; Stage IV Colorectal Cancer AJCC v8; Stage IV Ovarian Cancer AJCC v8; Stage IV Prostate Cancer AJCC v8; Stage IV Renal Cell Cancer AJCC v8; Stage IV Uterine Corpus Cancer AJCC v8; Stage IVA Bladder Cancer AJCC v8; Stage IVA Cervical Cancer AJCC v8; Stage IVA Colorectal Cancer AJCC v8; Stage IVA Ovarian Cancer AJCC v8; Stage IVA Prostate Cancer AJCC v8; Stage IVA Uterine Corpus Cancer AJCC v8; Stage IVB Bladder Cancer AJCC v8; Stage IVB Cervical Cancer AJCC v8; Stage IVB Colorectal Cancer AJCC v8; Stage IVB Ovarian Cancer AJCC v8; Stage IVB Prostate Cancer AJCC v8; Stage IVB Uterine Corpus Cancer AJCC v8; Stage IVC Colorectal Cancer AJCC v8
    • NCT04500392
      Not yet recruiting
      High-flow Nasal Cannula Oxygenation Decrease Hypoxia in Sedated Gastrointestinal Endoscopes in Obesity
      Conditions: Hypoxia; Gastric Cancer; Esophagus Cancer; Polyp of Colon; Colon Cancer
    • NCT04491942
      Not yet recruiting
      Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer
      Conditions: Advanced Bile Duct Carcinoma; Advanced Breast Carcinoma; Advanced Cervical Carcinoma; Advanced Endometrial Carcinoma; Advanced Esophageal Carcinoma; Advanced Gastric Carcinoma; Advanced Head and Neck Carcinoma; Advanced Lung Non-Small Cell Carcinoma; Advanced Lung Small Cell Carcinoma; Advanced Malignant Solid Neoplasm; Advanced Ovarian Carcinoma; Advanced Penile Carcinoma; Advanced Pleural Malignant Mesothelioma; Advanced Urothelial Carcinoma; Anatomic Stage III Breast Cancer AJCC v8; Anatomic Stage IIIA Breast Cancer AJCC v8; Anatomic Stage IIIB Breast Cancer AJCC v8; Anatomic Stage IIIC Breast Cancer AJCC v8; Anatomic Stage IV Breast Cancer AJCC v8; Clinical Stage III Gastric Cancer AJCC v8; Clinical Stage IV Gastric Cancer AJCC v8; Clinical Stage IVA Gastric Cancer AJCC v8; Clinical Stage IVB Gastric Cancer AJCC v8; Pathologic Stage III Gastric Cancer AJCC v8; Pathologic Stage IIIA Gastric Cancer AJCC v8; Pathologic Stage IIIB Gastric Cancer AJCC v8; Pathologic Stage IIIC Gastric Cancer AJCC v8; Pathologic Stage IV Gastric Cancer AJCC v8; Prognostic Stage III Breast Cancer AJCC v8; Prognostic Stage IIIA Breast Cancer AJCC v8; Prognostic Stage IIIB Breast Cancer AJCC v8; Prognostic Stage IIIC Breast Cancer AJCC v8; Prognostic Stage IV Breast Cancer AJCC v8; Stage III Cervical Cancer AJCC v8; Stage III Distal Bile Duct Cancer AJCC v8; Stage III Intrahepatic Bile Duct Cancer AJCC v8; Stage III Lung Cancer AJCC v8; Stage III Ovarian Cancer AJCC v8; Stage III Penile Cancer AJCC v8; Stage III Pleural Malignant Mesothelioma AJCC v8; Stage IIIA Cervical Cancer AJCC v8; Stage IIIA Distal Bile Duct Cancer AJCC v8; Stage IIIA Intrahepatic Bile Duct Cancer AJCC v8; Stage IIIA Lung Cancer AJCC v8; Stage IIIA Ovarian Cancer AJCC v8; Stage IIIA Penile Cancer AJCC v8; Stage IIIA Pleural Malignant Mesothelioma AJCC v8; Stage IIIA1 Ovarian Cancer AJCC v8; Stage IIIA2 Ovarian Cancer AJCC v8; Stage IIIB Cervical Cancer AJCC v8; Stage IIIB Distal Bile Duct Cancer AJCC v8; Stage IIIB Intrahepatic Bile Duct Cancer AJCC v8; Stage IIIB Lung Cancer AJCC v8; Stage IIIB Ovarian Cancer AJCC v8; Stage IIIB Penile Cancer AJCC v8; Stage IIIB Pleural Malignant Mesothelioma AJCC v8; Stage IIIC Lung Cancer AJCC v8; Stage IIIC Ovarian Cancer AJCC v8; Stage IV Cervical Cancer AJCC v8; Stage IV Distal Bile Duct Cancer AJCC v8; Stage IV Intrahepatic Bile Duct Cancer AJCC v8; Stage IV Lung Cancer AJCC v8; Stage IV Ovarian Cancer AJCC v8; Stage IV Penile Cancer AJCC v8; Stage IV Pleural Malignant Mesothelioma AJCC v8; Stage IVA Cervical Cancer AJCC v8; Stage IVA Lung Cancer AJCC v8; Stage IVA Ovarian Cancer AJCC v8; Stage IVB Cervical Cancer AJCC v8; Stage IVB Lung Cancer AJCC v8; Stage IVB Ovarian Cancer AJCC v8; Triple-Negative Breast Carcinoma; Unresectable Urothelial Carcinoma
    • NCT04492488
      Recruiting
      A Study of MRG002 in Patients With HER2-Positive Advanced Solid Tumors and Locally Advanced or Metastatic Gastric/Gastroesophageal Junction (GEJ) Cancer
      Conditions: Advanced Solid Tumors; Advanced or Metastatic Gastric Cancer; Advanced or Metastatic Gastroesophageal Junction Cancer
    • NCT04493125
      Not yet recruiting
      The Effect of Mosapride Citrate on Gastrointestinal Motility After Gastrectomy: Prospective, Double Blind Placebo-controlled Study
      Conditions: Stomach Cancer
    • NCT04490668
      Completed
      Human Albumin and Anastomotic Leakage After Gastric Cancer Surgery
      Conditions: Gastric Cancer; Anastomotic Leak
    • NCT04487717
      Enrolling by invitation
      Prospective Assessment of nProfiler® 1 on Prognosis and Chemotherapy Response for Gastric Cancer
      Conditions: Gastric Cancer
      Medical Conditions
      Sponsors and Collaborators
      Drug Interventions
      Conditions
      Rare Diseases
      Drug Interventions
      Dietary Supplements
      Sponsor/Collaborators
      Locations